Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

Long-acting (LA) glucagon-like peptide-1 (GLP-1) receptor agonists (RAs ... Development of antidrug antibodies are common with the LA GLP1-RAs (except for dulaglutide), but there is little ...

a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

[11] The absence of severe hypoglycemia is consistent with the glucose-dependent insulinotropic mechanism of GLP-1 receptor agonists. The rates of confirmed hypoglycemia were similar between the ...

to preserve muscle mass while patients are treated with weight-reducing drugs like GLP-1 receptor agonists. A phase 2 trial of the antibody, called EMBRAZE, is ongoing and due to read out next year.

For decades, Alzheimer's research has focused on examining amyloid plaques in the brain and prescribing antibody therapeutics ... Research highlights how GLP-1 receptor agonists may improve ...

A large study of veterans with type 2 diabetes finds better short-term kidney outcomes with use of SGLT2 inhibitors vs GLP-1 receptor agonists.

No signal for an increase in suicidal ideation or attempts associated with GLP-1 use was seen across subgroups stratified by ...

Transenteric delivery via the RaniPill yielded 80% relative bioavailability versus SC and differences between PK parameters ...

Not everybody loses the same amount of weight on medications such as Ozempic and Saxenda—treatment indication, dosage, and ...

Medicines affecting the GLP-1 receptor are in vogue for weight loss right now. Zealand Pharma has GLP-1 candidates, but also a compelling alternative approach. BioAge Labs' lead program could ...